CRDF
Cardiff Oncology Inc
1.20$
-3.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4,545.5% | -7,066.8% | -8,147.0% | -4,610.1% | -3,492.1% | -5,423.7% | -4,457.6% | -6,417.8% | -8,761.7% | -6,329.3% | -5,518.7% | -6,395.1% | |
| 83.9% | 121.0% | 280.8% | 247.1% | 227.2% | 201.9% | 127.3% | 125.6% | 61.1% | 81.6% | 59.2% | 152.4% | |
| 739.4% | 1,260.7% | 1,969.6% | 794.7% | 575.4% | 361.8% | 482.2% | 900.8% | 1,102.6% | 924.0% | 696.9% | 960.0% | |
| 221.2% | 1,494.3% | 1,474.9% | 657.1% | 552.9% | 350.2% | 568.3% | 821.7% | 1,102.8% | – | – | – | |
| 156.4% | -44.1% | 285.6% | -619.0% | 25.9% | 446.4% | -178.8% | -498.3% | -98.4% | 1,345.9% | 464.4% | 367.5% | |
| 129.7% | 716.0% | 216.0% | 19.8% | 1.3% | 27.8% | 57.9% | 57.1% | 231.1% | 119.3% | 11.7% | 7.4% | |
| -107.1% | -713.6% | -6,517.8% | 4,745.0% | 6.1% | -27.6% | -57.9% | -36,615.0% | 9,883.2% | 7,417.0% | 2,010.0% | 226.3% | |
| 8,219.6% | 7,744.4% | 6,362.2% | 4,800.0% | 6,412.7% | 9,908.8% | 6,623.0% | 6.7% | 107.3% | – | – | – | |
| – | 20,276.6% | 6,362.2% | 4,971.5% | 8,485.2% | 4,953.3% | 6,623.0% | 9,874.7% | 19.4% | – | – | – | |
| 5,172.9% | 347.0% | -92.1% | -3,413.7% | -363.9% | – | – | 0.0% | – | – | – | – | |
| 5,172.9% | 20,623.6% | 604.0% | -1,263.0% | 4,339.6% | 4,937.2% | 37,517.0% | 9,874.7% | 19.4% | 0.0% | 7,874.1% | 435.2% | |
| 520.3% | 12,843.2% | -14,062.5% | -1,126.5% | 853.7% | -514.2% | 33,001.5% | -33,158.2% | 1,140.9% | 1,087.7% | 4,365.3% | -5,733.6% | |
| -4,675.2% | -7,782.8% | -8,363.0% | -4,629.9% | -3,493.4% | -5,451.5% | -4,515.5% | -6,474.9% | -8,992.7% | -6,448.6% | -5,530.5% | -6,402.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.